Canada-based PharmEng International has established a joint venture company in partnership with Beijing BRD Lixin PharmaTech of China to provide consulting and pharmaceutical development services in China. PharmEng will own 51 percent of the joint venture company, headquartered in Beijing, China and will operate under the name Beijing PharmEng BRD Lixin PharmaTech Consultation.
Lixin provides consulting services in the areas of GMP (good manufacturing practices), validation and engineering design to approximately 100 pharmaceutical manufacturers in China. Lixin's clients manufacture powders for injection, solutions for injections, oral liquids and other extracts used in Chinese medicines and other drug products.
PharmEng will provide Lixin with consulting services in US cGMP standards, European GMP and other areas of North American regulatory and compliance requirements. Lixin, with its client base, will provide PharmEng’s Keata with a resource base of manufacturers and distributors for the supply of API (active pharmaceutical ingredients) in addition to giving PharmEng a solid base for the expansion of consulting opportunities in China.
Due to the volume of the GMP support services and demand by Chinese pharmaceutical companies and the tightening up by the SFDA for compliance, the company is expecting major growth in its consulting and manufacturing businesses through its China growth strategy. PharmEng will become a channel for two-way pharmaceutical consulting and trade between North America and China for:
- Access to cost effective active pharmaceutical ingredients (APIs)
- Formulations and technology transfers for off-patent drugs
- Consulting services
- Exclusive agency and distribution agreements in North America
“PharmEng, with its local partners, is in a unique position to leverage its North American relationships and knowledge into the Asia Pacific Rim and China regions. PharmEng has the proven international experience to be a major player in the region's health sector growth by leveraging and sharing our knowledge of FDA/ Health Canada regulations with the region,” said Mr Alan Kwong, CEO and Chairman of PharmEng International Inc.